177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

Journal:
Journal of Clinical Oncology
Published:
DOI:
10.1200/jco-25-01553
Affiliations:
11
Authors:
31
Go to article
Institutions Authors Share
University of California, Los Angeles (UCLA), United States of America (USA)
27.500000
27.500000
27.500000
 0.89
VA Greater Los Angeles Healthcare System, United States of America (USA)
1.500000
 0.05
University of San Francisco (USF), United States of America (USA)
1.000000
 0.03
University of Washington (UW), United States of America (USA)
1.000000
 0.03
Interested in Biomedical Engineering?